Recruiting studies: Her2 Breast Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

S1501 Dual Observational and Randomized Cohort Study of Patients With Metastatic HER-2+ Breast Cancer at Risk of Cardiac
Phase 3 · 590 location(s) · SWOG Cancer Research Network · NCT03418961 Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Phase 1 · 40 location(s) · TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · NCT06625775 Combination Followed by Maintenance Chemotherapy Versus CDK4/6 Inhibitor Combined With Endocrine Therapy for HR Low/HER2
Phase 2 · 1 location(s) · Henan Cancer Hospital · NCT06176534 NEOadjuvant Abemaciclib and GIredestrant TriaL in Patients with ER-positive, HER2-negative Early Breast Cancer
Phase 2 · 8 location(s) · Fondazione Oncotech · NCT06259929 Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
Phase 1 · 29 location(s) · Novartis Pharmaceuticals · NCT06562192 A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.
Phase 1/Phase 2 · 22 location(s) · Forward Pharmaceuticals Co., Ltd. · NCT06064812 Pyrotinib Combined With Dalpiciclib Combined With Letrozole in ER-positive and HER2-positive Advanced Breast Cancer
Phase 2 · 1 location(s) · Zhejiang Cancer Hospital · NCT07014410 Real-World Treatment Pattern and Clinical Outcome With Influential Factors of HR+/HER2-aBC 1L Patients in China
Phase N/A · 1 location(s) · Novartis Pharmaceuticals · NCT07476170 Pilot Study of [68Ga]Ga-ABY-025 Imaging in Patients Undergoing Treatment With HER2-targeted Therapy
EARLY_Phase 1 · 1 location(s) · Vanderbilt-Ingram Cancer Center · NCT06828588 Neoadjuvant Therapy Study Guided by Drug Screening in Vitro for Human Epidermal Growth Factor Receptor 2 (HER2) Negative
Phase 1/Phase 2 · 1 location(s) · Peking University People's Hospital · NCT04836156 Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
Phase 2 · 1 location(s) · The Methodist Hospital Research Institute · NCT05305924 HR+/HER2- Advanced or Metastatic Breast Cancer Patients Treated With Sacituzumab Govitecan
Phase 2 · 10 location(s) · SOLTI Breast Cancer Research Group · NCT06236269 Clinical Study of HRS-8080 in Combination With Dalpiciclib Isethionate Tablets in Patients With Unresectable or Metastat
Phase 1/Phase 2 · 2 location(s) · Shandong Suncadia Medicine Co., Ltd. · NCT06167694 Trastuzumab Deruxtecan vs Endocrine Therapy in Low-HER2 HR+ Advanced Breast Cancer
Phase 2 · 1 location(s) · Yonsei University · NCT06837792 Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer
NA · 1 location(s) · Fudan University · NCT04281641 Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes for Advanced HER2-Negative Breast Cancer
Phase 1/Phase 2 · 1 location(s) · Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · NCT05981001 RC48 Plus Bevacizumab or Pyrotinib in HER2-Positive Metastatic Breast Cancer After T-DXd Failure: A Phase II Study
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07065435 Phase Ib/II Clinical Study of QLS1304 Combined With Endocrine Therapy in the Treatment of ER+/HER2- Breast Cancer Patien
Phase 1/Phase 2 · 1 location(s) · Qilu Pharmaceutical Co., Ltd. · NCT07235176 Trastuzumab Emtansine(T-DM1) After Trastuzumab Deruxtecan(T-DXd) in HER2-Positive Breast Cancer in Korea
Phase N/A · 1 location(s) · Seoul National University Hospital · NCT06928818 A Study of the Impact of Endocrine Therapy on Surgical Outcomes in People With Lobular Breast Cancer
Phase 2 · 7 location(s) · Memorial Sloan Kettering Cancer Center · NCT07483307 A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Phase 1 · 6 location(s) · Cogent Biosciences, Inc. · NCT07361562 Radiotherapy Followed by Chemotherapy Combined With Toripalimab in Local Advanced HR-positive,HER2-negative BC.
Phase 2 · 1 location(s) · First Affiliated Hospital of Zhejiang University · NCT06705127 A Multicenter, Single-Arm, Phase II Exploratory Study of Eribulin in Combination With Anlotinib for HER2-Negative Recurr
Phase 2 · 1 location(s) · Sun Yat-sen University · NCT07520760 Organoid-based Functional Precision Therapy for Advanced Breast Cancer
Phase 2 · 1 location(s) · Guangdong Provincial People's Hospital · NCT06102824 Retrospective Observational Study of the Safety and Toxicity Management of Abemaciclib in Combination with Adjuvant Horm
Phase N/A · 1 location(s) · University Hospital, Brest · NCT06621459 The Dosing Regimen of Pyrotinib in HER2-positive Advanced First-line Breast Cancer: a Phase II Clinical Study
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT06254690 Neoadjuvant Dose-dense Chemotherapy for HR+/HER2- Breast Cancer Patients With High Proliferation Index
Phase 2 · 1 location(s) · Shantou Central Hospital · NCT05728268 Study of ART6043 in Advanced/Metastatic Solid Tumors Patients (POLKA)
Phase 1/Phase 2 · 12 location(s) · Artios Pharma Ltd · NCT05898399 HS-10502 Combination Treatment in Patients With Advanced Solid Tumors
Phase 1 · 1 location(s) · Jiangsu Hansoh Pharmaceutical Co., Ltd. · NCT06769425 Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 13 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT05985655

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.